Global and China Multiple Sclerosis Drugs Market Insights, Forecast to 2026

Global and China Multiple Sclerosis Drugs Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Multiple Sclerosis Drugs Product Introduction
1.2 Market Segments
1.3 Key Multiple Sclerosis Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Multiple Sclerosis Drugs Market Size Growth Rate by Type
1.4.2 Injectable Medications
1.4.3 Oral Medications
1.4.4 Others
1.5 Market by Application
1.5.1 Global Multiple Sclerosis Drugs Market Size Growth Rate by Application
1.5.2 Adults
1.5.3 Children
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis Drugs Market Size, Estimates and Forecasts
2.1.1 Global Multiple Sclerosis Drugs Revenue 2015-2026
2.1.2 Global Multiple Sclerosis Drugs Sales 2015-2026
2.2 Global Multiple Sclerosis Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Multiple Sclerosis Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Multiple Sclerosis Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Multiple Sclerosis Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Multiple Sclerosis Drugs Revenue Forecast by Region (2021-2026)
3 Global Multiple Sclerosis Drugs Competitor Landscape by Players
3.1 Global Top Multiple Sclerosis Drugs Sales by Manufacturers
3.1.1 Global Multiple Sclerosis Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Multiple Sclerosis Drugs Manufacturers by Revenue
3.2.1 Global Multiple Sclerosis Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Multiple Sclerosis Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Multiple Sclerosis Drugs Revenue in 2019
3.2.5 Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Multiple Sclerosis Drugs Price by Manufacturers
3.4 Global Multiple Sclerosis Drugs Manufacturing Base Distribution, Product Types
3.4.1 Multiple Sclerosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Multiple Sclerosis Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Multiple Sclerosis Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Multiple Sclerosis Drugs Market Size by Type (2015-2020)
4.1.1 Global Multiple Sclerosis Drugs Sales by Type (2015-2020)
4.1.2 Global Multiple Sclerosis Drugs Revenue by Type (2015-2020)
4.1.3 Multiple Sclerosis Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Multiple Sclerosis Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Multiple Sclerosis Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Multiple Sclerosis Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Multiple Sclerosis Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Multiple Sclerosis Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Multiple Sclerosis Drugs Market Size by Application (2015-2020)
5.1.1 Global Multiple Sclerosis Drugs Sales by Application (2015-2020)
5.1.2 Global Multiple Sclerosis Drugs Revenue by Application (2015-2020)
5.1.3 Multiple Sclerosis Drugs Price by Application (2015-2020)
5.2 Multiple Sclerosis Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Multiple Sclerosis Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Multiple Sclerosis Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Multiple Sclerosis Drugs Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
6.1 China Multiple Sclerosis Drugs Market Size YoY Growth 2015-2026
6.1.1 China Multiple Sclerosis Drugs Sales YoY Growth 2015-2026
6.1.2 China Multiple Sclerosis Drugs Revenue YoY Growth 2015-2026
6.1.3 China Multiple Sclerosis Drugs Market Share in Global Market 2015-2026
6.2 China Multiple Sclerosis Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Multiple Sclerosis Drugs Players by Sales (2015-2020)
6.2.2 China Top Multiple Sclerosis Drugs Players by Revenue (2015-2020)
6.3 China Multiple Sclerosis Drugs Historic Market Review by Type (2015-2020)
6.3.1 China Multiple Sclerosis Drugs Sales Market Share by Type (2015-2020)
6.3.2 China Multiple Sclerosis Drugs Revenue Market Share by Type (2015-2020)
6.3.3 China Multiple Sclerosis Drugs Price by Type (2015-2020)
6.4 China Multiple Sclerosis Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Multiple Sclerosis Drugs Sales Forecast by Type (2021-2026)
6.4.2 China Multiple Sclerosis Drugs Revenue Forecast by Type (2021-2026)
6.4.3 China Multiple Sclerosis Drugs Price Forecast by Type (2021-2026)
6.5 China Multiple Sclerosis Drugs Historic Market Review by Application (2015-2020)
6.5.1 China Multiple Sclerosis Drugs Sales Market Share by Application (2015-2020)
6.5.2 China Multiple Sclerosis Drugs Revenue Market Share by Application (2015-2020)
6.5.3 China Multiple Sclerosis Drugs Price by Application (2015-2020)
6.6 China Multiple Sclerosis Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Multiple Sclerosis Drugs Sales Forecast by Application (2021-2026)
6.6.2 China Multiple Sclerosis Drugs Revenue Forecast by Application (2021-2026)
6.6.3 China Multiple Sclerosis Drugs Price Forecast by Application (2021-2026)
7 North America
7.1 North America Multiple Sclerosis Drugs Market Size YoY Growth 2015-2026
7.2 North America Multiple Sclerosis Drugs Market Facts & Figures by Country
7.2.1 North America Multiple Sclerosis Drugs Sales by Country (2015-2020)
7.2.2 North America Multiple Sclerosis Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Multiple Sclerosis Drugs Market Size YoY Growth 2015-2026
8.2 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country
8.2.1 Europe Multiple Sclerosis Drugs Sales by Country
8.2.2 Europe Multiple Sclerosis Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Multiple Sclerosis Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Multiple Sclerosis Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Multiple Sclerosis Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Multiple Sclerosis Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Multiple Sclerosis Drugs Market Facts & Figures by Country
10.2.1 Latin America Multiple Sclerosis Drugs Sales by Country
10.2.2 Latin America Multiple Sclerosis Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Multiple Sclerosis Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Country
11.2.2 Middle East and Africa Multiple Sclerosis Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Biogen
12.1.1 Biogen Corporation Information
12.1.2 Biogen Description and Business Overview
12.1.3 Biogen Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Biogen Multiple Sclerosis Drugs Products Offered
12.1.5 Biogen Recent Development
12.2 Sanofi
12.2.1 Sanofi Corporation Information
12.2.2 Sanofi Description and Business Overview
12.2.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Sanofi Multiple Sclerosis Drugs Products Offered
12.2.5 Sanofi Recent Development
12.3 Novartis
12.3.1 Novartis Corporation Information
12.3.2 Novartis Description and Business Overview
12.3.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Novartis Multiple Sclerosis Drugs Products Offered
12.3.5 Novartis Recent Development
12.4 Teva
12.4.1 Teva Corporation Information
12.4.2 Teva Description and Business Overview
12.4.3 Teva Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Teva Multiple Sclerosis Drugs Products Offered
12.4.5 Teva Recent Development
12.5 Merck KGaA
12.5.1 Merck KGaA Corporation Information
12.5.2 Merck KGaA Description and Business Overview
12.5.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Merck KGaA Multiple Sclerosis Drugs Products Offered
12.5.5 Merck KGaA Recent Development
12.6 Bayer
12.6.1 Bayer Corporation Information
12.6.2 Bayer Description and Business Overview
12.6.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Bayer Multiple Sclerosis Drugs Products Offered
12.6.5 Bayer Recent Development
12.7 ACORDA
12.7.1 ACORDA Corporation Information
12.7.2 ACORDA Description and Business Overview
12.7.3 ACORDA Sales, Revenue and Gross Margin (2015-2020)
12.7.4 ACORDA Multiple Sclerosis Drugs Products Offered
12.7.5 ACORDA Recent Development
12.8 Mallinckrodt
12.8.1 Mallinckrodt Corporation Information
12.8.2 Mallinckrodt Description and Business Overview
12.8.3 Mallinckrodt Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Mallinckrodt Multiple Sclerosis Drugs Products Offered
12.8.5 Mallinckrodt Recent Development
12.11 Biogen
12.11.1 Biogen Corporation Information
12.11.2 Biogen Description and Business Overview
12.11.3 Biogen Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Biogen Multiple Sclerosis Drugs Products Offered
12.11.5 Biogen Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Multiple Sclerosis Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Multiple Sclerosis Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Multiple Sclerosis Drugs Market Segments
Table 2. Ranking of Global Top Multiple Sclerosis Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Multiple Sclerosis Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Injectable Medications
Table 5. Major Manufacturers of Oral Medications
Table 6. Major Manufacturers of Others
Table 7. Global Multiple Sclerosis Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Multiple Sclerosis Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Multiple Sclerosis Drugs Sales by Regions 2015-2020 (K Units)
Table 10. Global Multiple Sclerosis Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Multiple Sclerosis Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Multiple Sclerosis Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 13. Global Multiple Sclerosis Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Multiple Sclerosis Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Multiple Sclerosis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis Drugs as of 2019)
Table 17. Multiple Sclerosis Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Multiple Sclerosis Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Multiple Sclerosis Drugs Price (2015-2020) (USD/Unit)
Table 20. Multiple Sclerosis Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Multiple Sclerosis Drugs Product Type
Table 22. Date of International Manufacturers Enter into Multiple Sclerosis Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Multiple Sclerosis Drugs Sales by Type (2015-2020) (K Units)
Table 25. Global Multiple Sclerosis Drugs Sales Share by Type (2015-2020)
Table 26. Global Multiple Sclerosis Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Multiple Sclerosis Drugs Revenue Share by Type (2015-2020)
Table 28. Multiple Sclerosis Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Multiple Sclerosis Drugs Sales Share by Type (2021-2026)
Table 30. Global Multiple Sclerosis Drugs Sales by Application (2015-2020) (K Units)
Table 31. Global Multiple Sclerosis Drugs Sales Share by Application (2015-2020)
Table 32. Global Multiple Sclerosis Drugs Sales Share by Application (2021-2026)
Table 33. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Application (2021-2026)
Table 34. Global Multiple Sclerosis Drugs Revenue by Application (2015-2020) (US$ Million)
Table 35. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 36. China Multiple Sclerosis Drugs Sales (K Units) of Key Companies (2015-2020)
Table 37. China Multiple Sclerosis Drugs Sales Share by Company (2015-2020)
Table 38. China Multiple Sclerosis Drugs Revenue (US$ Million) by Company (2015-2020)
Table 39. China Multiple Sclerosis Drugs Sales (K Units) by Type (2015-2020)
Table 40. China Multiple Sclerosis Drugs Sales Share by Type (2015-2020)
Table 41. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 42. China Multiple Sclerosis Drugs Price (K Units) by Type (2015-2020)
Table 43. China Multiple Sclerosis Drugs Sales (K Units) by Type (2021-2026)
Table 44. China Multiple Sclerosis Drugs Sales Share by Type (2021-2026)
Table 45. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 46. China Multiple Sclerosis Drugs Revenue Share by Type (2021-2026)
Table 47. China Multiple Sclerosis Drugs Price (K Units) by Type (2021-2026)
Table 48. China Multiple Sclerosis Drugs Sales (K Units) by Application (2015-2020)
Table 49. China Multiple Sclerosis Drugs Sales Share by Application (2015-2020)
Table 50. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 51. China Multiple Sclerosis Drugs Sales (K Units) by Application (2021-2026)
Table 52. China Multiple Sclerosis Drugs Sales Share by Application (2021-2026)
Table 53. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 54. China Multiple Sclerosis Drugs Revenue Share by Application (2021-2026)
Table 55. North America Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units)
Table 56. North America Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020)
Table 57. North America Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. North America Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020)
Table 59. Europe Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units)
Table 60. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020)
Table 61. Europe Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 62. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020)
Table 63. Asia Pacific Multiple Sclerosis Drugs Sales by Region (2015-2020) (K Units)
Table 64. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2015-2020)
Table 65. Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2015-2020) (US$ Million)
Table 66. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region (2015-2020)
Table 67. Latin America Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units)
Table 68. Latin America Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020)
Table 69. Latin Americaa Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 70. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units)
Table 72. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020)
Table 73. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 74. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020)
Table 75. Biogen Corporation Information
Table 76. Biogen Description and Business Overview
Table 77. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Biogen Multiple Sclerosis Drugs Product
Table 79. Biogen Recent Development
Table 80. Sanofi Corporation Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Sanofi Product
Table 84. Sanofi Recent Development
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Novartis Product
Table 89. Novartis Recent Development
Table 90. Teva Corporation Information
Table 91. Teva Description and Business Overview
Table 92. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Teva Product
Table 94. Teva Recent Development
Table 95. Merck KGaA Corporation Information
Table 96. Merck KGaA Description and Business Overview
Table 97. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Merck KGaA Product
Table 99. Merck KGaA Recent Development
Table 100. Bayer Corporation Information
Table 101. Bayer Description and Business Overview
Table 102. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Bayer Product
Table 104. Bayer Recent Development
Table 105. ACORDA Corporation Information
Table 106. ACORDA Description and Business Overview
Table 107. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. ACORDA Product
Table 109. ACORDA Recent Development
Table 110. Mallinckrodt Corporation Information
Table 111. Mallinckrodt Description and Business Overview
Table 112. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Mallinckrodt Product
Table 114. Mallinckrodt Recent Development
Table 115. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 116. Key Challenges
Table 117. Market Risks
Table 118. Main Points Interviewed from Key Multiple Sclerosis Drugs Players
Table 119. Multiple Sclerosis Drugs Customers List
Table 120. Multiple Sclerosis Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis Drugs Product Picture
Figure 2. Global Multiple Sclerosis Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Injectable Medications Product Picture
Figure 4. Oral Medications Product Picture
Figure 5. Others Product Picture
Figure 6. Global Multiple Sclerosis Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Adults
Figure 8. Children
Figure 9. Multiple Sclerosis Drugs Report Years Considered
Figure 10. Global Multiple Sclerosis Drugs Market Size 2015-2026 (US$ Million)
Figure 11. Global Multiple Sclerosis Drugs Sales 2015-2026 (K Units)
Figure 12. Global Multiple Sclerosis Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Multiple Sclerosis Drugs Sales Market Share by Region (2015-2020)
Figure 14. Global Multiple Sclerosis Drugs Sales Market Share by Region in 2019
Figure 15. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2015-2020)
Figure 16. Global Multiple Sclerosis Drugs Revenue Market Share by Region in 2019
Figure 17. Global Multiple Sclerosis Drugs Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Multiple Sclerosis Drugs Revenue in 2019
Figure 19. Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Multiple Sclerosis Drugs Sales Market Share by Type (2015-2020)
Figure 21. Global Multiple Sclerosis Drugs Sales Market Share by Type in 2019
Figure 22. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2015-2020)
Figure 23. Global Multiple Sclerosis Drugs Revenue Market Share by Type in 2019
Figure 24. Global Multiple Sclerosis Drugs Market Share by Price Range (2015-2020)
Figure 25. Global Multiple Sclerosis Drugs Sales Market Share by Application (2015-2020)
Figure 26. Global Multiple Sclerosis Drugs Sales Market Share by Application in 2019
Figure 27. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2015-2020)
Figure 28. Global Multiple Sclerosis Drugs Revenue Market Share by Application in 2019
Figure 29. China Multiple Sclerosis Drugs Sales Growth Rate 2015-2026 (K Units)
Figure 30. China Multiple Sclerosis Drugs Revenue Growth Rate 2015-2026 (US$ Million)
Figure 31. China Multiple Sclerosis Drugs Market Share in Global Market 2015-2026
Figure 32. China 5 and 10 Largest Multiple Sclerosis Drugs Players Market Share by Revenue in Multiple Sclerosis Drugs in 2019
Figure 33. China Multiple Sclerosis Drugs Revenue Share by Type (2015-2020)
Figure 34. China Multiple Sclerosis Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 35. China Multiple Sclerosis Drugs Revenue Share by Application (2015-2020)
Figure 36. China Multiple Sclerosis Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 37. North America Multiple Sclerosis Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 38. North America Multiple Sclerosis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 39. North America Multiple Sclerosis Drugs Sales Market Share by Country in 2019
Figure 40. North America Multiple Sclerosis Drugs Revenue Market Share by Country in 2019
Figure 41. U.S. Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 42. U.S. Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Canada Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 44. Canada Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Europe Multiple Sclerosis Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 46. Europe Multiple Sclerosis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 47. Europe Multiple Sclerosis Drugs Sales Market Share by Country in 2019
Figure 48. Europe Multiple Sclerosis Drugs Revenue Market Share by Country in 2019
Figure 49. Germany Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. Germany Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. France Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. France Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. U.K. Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. U.K. Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Italy Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 56. Italy Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Russia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 58. Russia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Asia Pacific Multiple Sclerosis Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 60. Asia Pacific Multiple Sclerosis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region in 2019
Figure 62. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region in 2019
Figure 63. China Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. China Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. Japan Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. South Korea Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. India Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Australia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Taiwan Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Indonesia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Thailand Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Malaysia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Philippines Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 84. Vietnam Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Latin America Multiple Sclerosis Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Multiple Sclerosis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Multiple Sclerosis Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Middle East and Africa Multiple Sclerosis Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 96. Middle East and Africa Multiple Sclerosis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country in 2019
Figure 99. Turkey Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 100. Turkey Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Saudi Arabia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. U.A.E Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Porter's Five Forces Analysis
Figure 106. Multiple Sclerosis Drugs Value Chain
Figure 107. Channels of Distribution
Figure 108. Distributors Profiles
Figure 109. Bottom-up and Top-down Approaches for This Report
Figure 110. Data Triangulation
Figure 111. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Fingolimod Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Multiple Sclerosis Drugs Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78

The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provi......

Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118

Market Overview of Global Multiple Sclerosis market: According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years. Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......

Fingolimod - Global Market Insights and Sales Trends 2024

Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 77

The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......

Global Fingolimod Market Research Report 2023, Forecast to 2028

Published: 19-Dec-2023        Price: US 2680 Onwards        Pages: 133

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......

Global Fingolimod Professional Survey Report 2023, Forecast to 2028

Published: 19-Dec-2023        Price: US 3280 Onwards        Pages: 101

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......

Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024

Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 96

This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......

Global Multiple Sclerosis Drugs Market Research Report 2023

Published: 25-Oct-2023        Price: US 2900 Onwards        Pages: 87

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Biogen - Sanofi - Novartis - Teva - Merck KGaA - Bayer - ACORDA - Mallinckrodt Segment by Type - Injectable......

Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 13-Jun-2023        Price: US 3260 Onwards        Pages: 122

Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs